

Table S3. Tabular description of all the selected eligible *in vivo* RCTs human studies of TMD, in terms of level of significance in subjective and objective assessments of pain, functionality improvement and anxiety reduction/QoL improvement. The abbreviations are listed in Supplementary File S2.

[illegible]

Borges et al., 2018, Brazil [88]	Y	N	NS	NS	NS	NS	Y	N	NS	NS	NS	NS
Brochado et al., 2018, Brazil [89]	Y	N	NS	NS	NS	NS	Y	N	Y	N	NS	NS
Rodrigues et al., 2018, Brazil [90]	Y	N	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Peimani et al., 2018, Iran [91]	Y	N	NS	NS	NS	NS	Y	N	NS	NS	NS	NS
Nadershah et al., 2019, Saudi Arabia [92]	Y	N	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Magri et al., 2019, Brazil [93]	Y	N	NS	NS	NS	NS	Y	N	NS	NS	NS	NS
Al-Quisi et al., 2019, Iraq [94]	Y	N	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Herpich et al., 2019, Brazil [95]	Y	N	NS	NS	Y	N	N	Y	NS	NS	NS	NS
Khairnar et al., 2019, India [96]	Y	N	NS	NS	NS	NS	Y	N	NS	NS	NS	NS
Sobral et al., 2020, Brazil [97]	Y	N	NS	NS	NS	NS	Y	N	Y	N	NS	NS
Maracci et al., 2020, Brazil [98]	NS	NS	NS	NS	NS	NS	N	Y	N	Y	NS	NS
Chellappa et al., 2020, India [99]	Y	N	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS
Monteiro et al., 2020, Brazil [100]	Y	N	NS	NS	NS	NS	Y	N	NS	NS	NS	NS